SouthViews No. 203, 24 July 2020
Coronavirus pandemic: the vaccine as exit strategy
A GLOBAL HURDLE RACE AGAINST TIME WITH A SPLIT JURY
By Francisco Colman Sercovich
Sars-CoV-2, a novel pathogen, submits a stern warning, a clarion call, on the huge human costs of shortsightedness, inaction and lessons lost in the face of common predicaments at the global level. Yet, a number of key actors remain oblivious, including ethically-challenged politicians seeking to elbow their way to the front of the queue at the expense of the poorest and most vulnerable nations and communities. Contrary to expectations being formed, a safe and effective vaccine for the Covid-19 strain once, if ever, attained, is the best way out but unlikely to do as a silver bullet in the midst of the complexities and unknowns at play.
As a result of the harmful impact of the pandemic and ensuing policy aftermath, the world runs the risk of squandering the gains barely made in the fight against poverty over the last few decades – a looming scenario of egregious global governance failure, in view of the eight close calls recently received (three flu epidemics or near-flu epidemics, two Sars episodes, one Mers episode, Zika & Ebola). A promptly and universally distributed vaccine promises to prevent future disease outbreaks. However, many scientific, economic and distributional hurdles stand in the way. Whilst each day counts, the survival of hundreds of millions of lives hangs in the balance as health issues and those pertaining to livelihoods, nutrition, schooling and deprivation are so closely interdependent. Can we rule out the need to resort to internationally sanctioned legal remedies as an inescapable response?
Download the SouthViews:
Coronavirus pandemic: the vaccine as exit strategy – A GLOBAL HURDLE RACE AGAINST TIME WITH A SPLIT JURY
This article was tagged: Access to Medicines, Affordable Medicines, Civil Society (CSOs), Climate Change, Coronavirus, COVID-19, Debt Sustainability, Diagnostics, Economic Crisis, Financial Crisis, Flexibilities, Foreign Direct Investment (FDI), Generic Medicines, Global Health, Global Public Good, Global Value Chains (GVCs), Globalization, Health, Innovation, Intellectual Property, International Cooperation, Multilateralism, Multinational Corporations (MNCs), Pandemic, Patent, Pharmaceuticals, Public Health, Research and Development (R&D), Sustainable Development Goals (SDGs), Trade, TRIPS, Vaccines, WHO, World Health Organization (WHO), World Trade Organization (WTO), WTO